Skip to main content
65 search results for:

bDMARDS 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 20-06-2017 | Rheumatoid arthritis | Conference report | Article
    EULAR 2017

    Reassuring findings on cancer risk in RA patients prescribed bDMARDs

    “Our data should be reassuring bearing in mind the widespread current use of anti-TNF drugs to treat RA,” he said, and the fact that “previously we knew a lot less about the cancer risk with other bDMARDS.”

  2. 06-06-2022 | EULAR 2022 | Conference coverage | Article

    DMARD treatment has ‘profound anticoagulant effects’ in early RA

    Analysis of data from the NORD-STAR study suggests that people with early rheumatoid arthritis have increased levels of coagulation biomarkers, putting them at increased risk for venous thromboembolism, and initial treatment with DMARDs can help reduce this imbalance.

  3. 16-08-2021 | Temporal cell arteritis | Teaser

    New additions to the Adis Journal Club

    A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

  4. 08-01-2022 | Total hip replacement | Adis Journal Club | Article
    Rheumatology and Therapy

    Total Hip Replacement in Patients with Rheumatoid Arthritis: Trends in Incidence and Complication Rates Over 35 Years

    Whether increased use of bDMARDs further reduces the need for THR and rate of postoperative complications remains to be elucidated.

  5. 08-02-2022 | Temporal cell arteritis | Teaser

    Rituximab and rheumatology practice in the COVID-19 era

    How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

  6. 22-09-2021 | bDMARDS | Adis Journal Club | Article
    Clinical Drug Investigation

    Prescribing Trends of Biologic Disease-Modifying Anti-rheumatic Drugs Using a Claims Database from 6 Million People in Japan

    Future studies must accumulate evidence on the long-term efficacy and safety of bDMARDs.

  7. 24-05-2021 | ACR 2021 | Teaser

    ACR Convergence 2021 highlights

    3–9 November: Keep up with the latest news and interviews from the conference.

  8. 06-09-2021 | Pneumonia | Teaser

    Anifrolumab for the treatment of lupus

    Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

  9. 04-03-2021 | Psoriatic arthritis | Adis Journal Club | Article
    Drugs

    Secukinumab: A Review in Psoriatic Arthritis

    In conclusion, secukinumab is effective across all key PsA domains and is generally well tolerated, and thus represents a useful treatment alternative to TNFi and other bDMARDs in adult patients with active PsA.

  10. 06-07-2021 | Psoriatic arthritis | News | Article

    Biologics may reduce PsA risk in patients with psoriasis

    Taken together, the study results suggest that “[e]arly therapeutic intervention with bDMARDs may delay or reduce the risk of PsA development in patients with moderate-to-severe chronic plaque psoriasis,” write Gisondi and team in the Annals of the Rheumatic Diseases .

  11. 26-10-2020 | Vitamin D | Teaser

    Get ready for ACR Convergence 2020

    5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

  12. 07-05-2021 | Treatment tapering | News | Article

    Biologic treatment spacing feasible for some rheumatic disease patients

    Weekly subcutaneous bDMARDs, such as etanercept, were given every 2 weeks, while bDMARDs such as adalimumab normally administered every 2 weeks were administered every 4 weeks.

  13. 04-06-2021 | EULAR 2021 | Conference coverage | Article

    Uveitis risk warning in JIA patients discontinuing DMARD therapy

    Patients with juvenile idiopathic arthritis are at high risk for uveitis in the first 24 months of discontinuing DMARD therapy, findings from the EULAR 2021 Virtual Congress indicate.

  14. 10-05-2021 | Temporal cell arteritis | Teaser

    Febuxostat and cardiovascular risk in people with gout

    How will the FAST trial results impact regulatory guidance & clinical practice?

  15. 30-04-2021 | Rheumatoid arthritis | News | Article

    Clinical differences in baricitinib and tofacitinib effectiveness in rheumatoid arthritis

    “Results suggest that [tofacitinib] may be less effective in patients resistant to multiple bDMARDs, while [baricitinib] may be more effective after 24 weeks of treatment,” say Yoshiya Tanaka and co-researchers, from the University of Occupational and Environmental Health in Kitakyushu, Japan.

  16. 16-04-2021 | Rheumatoid arthritis | News | Article

    Real-world data reinforce benefit of optimizing methotrexate before starting biologics

    The study authors write in Rheumatology that “the guidelines only allow addition of [bDMARDs] or other conventional synthetic DMARDs (csDMARDs) to [methotrexate] treatment when monotherapy has been fully optimized (dose and route).”

  17. 13-01-2021 | Rheumatoid arthritis | News | Article

    Age, bone erosions, disease activity predict multiple biologic failure in RA

    Of these participants, 10% had multirefractory RA, defined as insufficient responses to at least two bDMARDs with different modes of action or three bDMARDs of any type.

  18. 18-11-2020 | Temporal cell arteritis | Teaser

    Telemedicine in rheumatology

    Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

  19. 06-06-2020 | EULAR 2020 | Conference coverage | Article

    COVID-19 hospitalization: What do the data tell us?

    The vast majority of patients were taking TNF inhibitors, at 63.2%, and among patients receiving treatment with bDMARDs or tsDMARDs overall, 1.14% were admitted to hospital and 21.1% died.

  20. 03-04-2020 | COVID-19 | News | Article

    Preliminary findings suggest no need for preventive DMARD withdrawal during COVID-19 pandemic

    “[O]ur preliminary experience shows that patients with chronic arthritis treated with bDMARDs or tsDMARDs do not seem to be at increased risk of respiratory or life-threatening complications from SARS-CoV-2 compared with the general population,” Monti and colleagues write in a letter published in the Annals of the Rheumatic Diseases .

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.